Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rare uterine cancers.

Sheetal Acharya1, Martee L Hensley, Anthony C Montag

  • 1UP Hematology Associates, Marquette, MI, USA.

The Lancet. Oncology
|December 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in nanocarrier-enabled theranostic strategies for lung cancer diagnosis and management.

Journal of biomaterials science. Polymer edition·2026
Same author

A Case of Three Synchronous Primary Lung Cancers of Distinct Histologies in a Patient With Severe Chronic Obstructive Pulmonary Disease.

Cureus·2026
Same author

Ovarian cancer cell glucocorticoid receptor activation increases myeloid-derived suppressor cell tumor infiltration.

Endocrinology·2026
Same author

Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.

Breast (Edinburgh, Scotland)·2026
Same author

Reverse Psychology in Pediatric Dentistry: A Narrative Review.

Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995)·2026
Same author

Evaluating the presence of <i>aggregatibacter actinomycetemcomitans</i>, <i>porphyromonas gingivalis</i> levels in patient's self- ligating brackets.

Bioinformation·2025
Same journal

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026
Same journal

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same journal

Co-medications and gut microbiome in NSCLC immunotherapy.

The Lancet. Oncology·2026
Same journal

Carcinogenicity of butyl benzyl phthalate, dibutyl phthalate, and diisononyl phthalate.

The Lancet. Oncology·2026
Same journal

New report sheds light on cancer disparities in the USA.

The Lancet. Oncology·2026
Same journal

Review highlights gaps in South Africa's cancer care.

The Lancet. Oncology·2026
See all related articles

This review covers rare uterine cancers like papillary serous carcinomas and sarcomas. It details their epidemiology, characteristics, and prognoses to guide treatment for these aggressive, less common malignant diseases.

Area of Science:

  • Gynecologic Oncology
  • Pathology

Background:

  • Endometrioid endometrial cancer is the most common uterine malignancy.
  • Less common uterine cancers, including carcinomas and sarcomas, are often aggressive and disproportionately contribute to mortality.
  • Notable rare uterine malignancies include papillary serous carcinomas, clear-cell carcinomas, carcinosarcomas, stromal sarcomas, and leiomyosarcomas.

Purpose of the Study:

  • To summarize the epidemiology, clinical characteristics, and prognoses of rare uterine malignancies.
  • To provide clinicians with available information to guide treatment decisions for uncommon uterine cancers.

Main Methods:

  • Literature review and synthesis of existing data on rare uterine cancers.
  • Analysis of epidemiological trends, clinical presentations, and survival outcomes.

Related Experiment Videos

Main Results:

  • Rare uterine cancers exhibit diverse clinical behaviors and prognoses.
  • Aggressive subtypes like papillary serous carcinomas and sarcomas are associated with higher mortality.
  • Limited randomized data exists for many of these uncommon conditions.

Conclusions:

  • Understanding the specific characteristics of rare uterine cancers is crucial for effective management.
  • Clinical guidance for these diseases relies on synthesizing available evidence due to their rarity.
  • Further research is needed to improve treatment strategies and outcomes for patients with uncommon uterine malignancies.